Clinical Trials
7
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (100.0%)The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06616727
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus
Phase 1
Not yet recruiting
- Conditions
- Lupus Erythematosis
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06468683
- Locations
- 🇨🇳
Shanghai jiaotong University School of Medicine,Renji Hospital, 上海市, 上海市, China
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Phase 1
Recruiting
- Conditions
- Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma
- Interventions
- Drug: SNC115 injection
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT06384482
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Phase 1
Recruiting
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: After preconditioning with chemotherapy, F01 will be evaluated.
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT06206902
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
Phase 1
Recruiting
- Conditions
- Recurrent Glioblastoma Multiforme
- Interventions
- Drug: SNC-109 CAR-T Cells
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05868083
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
- Prev
- 1
- 2
- Next
News
No news found